Effect of human immunodeficiency virus-1 infection on treatment outcome of acute salpingitis

Obstetrics and Gynecology

Volumn 107, Issue 4, 2006, Pages 807-812

  Mugo, Nelly R ^d   Kiehlbauch, Julia A ^a   Nguti, Rosemary ^d   Meier, Amalia ^d   Gichuhi, Joseph W ^d   Stamm, Walter E ^d   Cohen, Craig R ^b,c  

^a MARYLAND DEPARTMENT OF HEALTH AND MENTAL HYGIENE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

CEFOTETAN; CLINDAMYCIN; DOXYCYCLINE; METRONIDAZOLE; ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LAPAROSCOPY; LENGTH OF STAY; MAJOR CLINICAL STUDY; NONHUMAN; PELVIS ABSCESS; PRIORITY JOURNAL; SALPINGITIS; SERODIAGNOSIS; SURGICAL DRAINAGE; TREATMENT OUTCOME; TREATMENT RESPONSE; ACUTE DISEASE; ADOLESCENT; CASE CONTROL STUDY; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; FOLLOW UP; INTRAVENOUS DRUG ADMINISTRATION; METHODOLOGY; NONPARAMETRIC TEST; ORAL DRUG ADMINISTRATION; PELVIC INFLAMMATORY DISEASE; PREVALENCE; PROBABILITY; PROSPECTIVE STUDY; RISK ASSESSMENT;

ACUTE DISEASE; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; CASE-CONTROL STUDIES; CEFOTETAN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXYCYCLINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HIV SERONEGATIVITY; HIV SEROPOSITIVITY; HUMANS; INJECTIONS, INTRAVENOUS; LAPAROSCOPY; LENGTH OF STAY; PELVIC INFLAMMATORY DISEASE; PREVALENCE; PROBABILITY; PROSPECTIVE STUDIES; RISK ASSESSMENT; SALPINGITIS; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 33646090152     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.AOG.0000207597.70524.e8     Document Type: Article

References (19)

1. Westrom L, Joesoef R, Reynolds G, Hagdu A, Thompson SE. Pelvic inflammatory disease and fertility: a cohort study of 1,844 women with laparoscopically verified disease and 657 control women with normal laparoscopic results. Sex Transm Dis 1992;19:185-92.
2. Kamenga MC, De Cock KM, St Louis ME, Toure CK, Zakaria S, N'gbichi JM, et al. The impact of human immunodeficiency virus infection on pelvic inflammatory disease: a case-control study in Abidjan, Ivory Coast. Am J Obstet Gynecol 1995;172:919-25.
3. De Cock KM, Brun-Vezinet F, Soro B. HIV-1 and HIV-2 infections and AIDS in West Africa. AIDS 1991;5:S21-8.
4. Ojwang AW, Lema VM, Wanjala SH. HIV infection among patients with acute pelvic inflammatory disease at the Kenyatta National Hospital, Nairobi, Kenya. East Afr Med J 1993;70:506-11.
5. Hoegsberg B, Abulafia O, Sedlis A, Feldman J, DesJalais D, Landesman S, et al. Sexually transmitted diseases and human immunodeficiency virus infection among women with pelvic inflammatory disease. Am J Obstet Gynecol 1990;163:1135-9.
6. Cohen CR, Sinei S, Reilly M, Bukusi E, Eschenbach D, Holmes KK, et al. Effect of human immunodeficiency virus type 1 infection upon acute salpingitis: a laparoscopic study. J Infect Dis 1998;178:1352-8.
7. Kenya demographic and health survey. Nairobi, Kenya: Central Bureau of Statistics, Ministry of Planning and National Development; 2003.
8. 1998 guidelines for treatment of sexually transmitted diseases. Centers for Disease Control and Prevention. MMWR Recomm Rep 1998;47:1-111.
9. Sexually transmitted diseases treatment guidelines 2002. Centers for Disease Control and Prevention. MMWR Recomm Rep 2002;51:1-78.
10. Barbosa C, Macasaet M, Brockmann S, Sierra MF, Xia Z, Duerr A. Pelvic inflammatory disease and human immunodeficiency virus infection. Obstet Gynecol 1997;89:65-70.
11. Ness RB, Soper DE, Holley RL, Peipert J, Randall H, Sweet RL, et al. Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Randomized Trial. Am J Obstet Gynecol 2002;186:929-37.
12. Haggerty CL, Ness RB, Amortegui A, Hendrix SL, Hillier SL, Holley RL, et al. Endometritis does not predict reproductive morbidity after pelvic inflammatory disease. Am J Obstet Gynecol 2003;188:141-8.
13. McCormack WM, Nowroozi K, Alpert S, Sackel SG, Lee YH, Lowe EW, et al. Acute pelvic inflammatory disease: characteristics of patients with gonococcal and nongonococcal infection and evaluation of their response to treatment with aqueous procaine penicillin G and spectinomycin hydrochloride. Sex Transm Dis 1977;4:125-31.
14. Hager WD, Eschenbach DA, Spence MR, Sweet RL. Criteria for diagnosis and grading of salpingitis. Obstet Gynecol 1983;61:113-4.
15. Wasserheit JN, Bell TA, Kiviat NB, Wolner-Hanssen P, Zabriskie V, Kirby BD, et al. Microbial causes of proven pelvic inflammatory disease and efficacy of clindamycin and tobramycin. Ann Inter Med 1986;104:187-93.
16. Korn AP, Landers DV, Green JR, Sweet RL. Pelvic inflammatory disease in human immunodeficiency virus-infected women. Obstet Gynecol 1993;82:765-8.
17. Irwin KL, Moorman AC, O'Sullivan MJ, Sperling R, Koestler ME, Soto I, et al. Influence of human immunodeficiency virus infection on pelvic inflammatory disease. Obstet Gynecol 2000;95:525-34.
18. Bukusi EA, Cohen CR, Stevens CE, Sinei S, Reilly M, Grieco V, et al. Effects of human immunodeficiency virus 1 infection on microbial origins of pelvic inflammatory disease and on efficacy of ambulatory oral therapy. Am J Obstet Gynecol 1999;181:1374-81.
19. Kahn JG, Walker CK, Washington AE, Landers DV, Sweet RL. Diagnosing pelvic inflammatory disease. A comprehensive analysis and considerations for developing a new model. JAMA 1991;266:2594-604.